First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [31] Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer
    Chen, Dawei
    Gao, Aiqin
    Zou, Bing
    Huang, Wei
    Shao, Qian
    Meng, Xiangjiao
    Zhang, Pinliang
    Tang, Xiaoyong
    Hu, Xudong
    Zhang, Yan
    Guo, Jun
    Zhao, Wei
    Fu, Lei
    Zhao, Changhong
    Yuan, Jiajia
    Yu, Jinming
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [33] Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
    Chunyan Yan
    Zhengxiong Li
    Jiayan Li
    Quan Zhao
    Wenxiu Cao
    Shuqing Li
    Ruigang Diao
    Scientific Reports, 15 (1)
  • [34] Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
    Qi, Wei-Xiang
    Xiang, Yi
    Zhao, Shengguang
    Chen, Jiayi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3199 - 3206
  • [35] Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
    Liu, Qiao
    Tan, Chongqing
    Yi, Lidan
    Wan, Xiaomin
    Peng, Liubao
    Li, Jianhe
    Luo, Xia
    Zeng, Xiaohui
    PLOS ONE, 2021, 16 (11):
  • [36] Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
    Casado, M. D. Isla
    Arriola, E.
    Garcia-Campelo, M. R.
    Tain, P. Diz
    Blanco, C. Marti
    Piqueras, M. M. Lopez-Brea
    Vega, A. L. Moreno
    Mateos, L. A. Leon
    Rodriguez, J. M. Oramas
    Calderon, V. Gutierrez
    Majem, M.
    Hernandez, A. Sanchez
    Aguado, C.
    Cabellos, R. Alvarez
    Ciriquian, J. L. Marti
    Paul, A. Moreno
    Perez, J. L. Firvida
    Mellen, A. Callejo
    Baez, L.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1063 - S1063
  • [37] Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer - a meta-analysis
    Chen, Ching-Yi
    Chen, Wang-Chun
    Hung, Chao-Ming
    Wei, Yu-Feng
    IMMUNOTHERAPY, 2021, 13 (14) : 1165 - 1178
  • [38] Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial
    Perol, M.
    Ahn, M. -J.
    Cheng, Y.
    Clarke, J.
    Dingemans, A. -M.
    Gay, C.
    Navarro, A.
    Schuler, M.
    Yoshida, T.
    Martinez, P.
    Anderson, E. S.
    Sands, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S206 - S207
  • [39] Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer
    Huang, Y.
    Tong, F.
    Zhang, R.
    Liu, P.
    Dong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S704 - S705
  • [40] Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
    Wei-Xiang Qi
    Yi Xiang
    Shengguang Zhao
    Jiayi Chen
    Cancer Immunology, Immunotherapy, 2021, 70 : 3199 - 3206
12345